41149 - Kidney Cancer: Drugs (Answered)

Mark Menzies
To ask the Secretary of State for Health, when he plans to make a decision on the drug Nivolumab becoming available under the Early Access to Medicines Scheme to treat patients with renal cell carcinoma.

George Freeman

The Medicines and Healthcare products Regulatory Agency (MHRA) issued a positive scientific opinion concerning the use of nivolumab for renal cell carcinoma under the Early Access to Medicines Scheme on 11 February 2016. This scientific opinion has now lapsed as nivolumab has received its marketing authorisation for use in for renal cell carcinoma from the European Commission.